Rdgl

  • Ecco la 69° Edizione del settimanale "Le opportunità di Borsa" dedicato ai consulenti finanziari ed esperti di borsa.

    Settimana difficile per i principali indici europei e americani, solo il Nasdaq resiste alle vendite grazie ai conti di Nvidia. Il leader dei chip per l’intelligenza artificiale ha riportato utili e prospettive superiori alle attese degli analisti, annunciando anche un frazionamento azionario (10 a 1). Gli investitori però valutano anche i toni restrittivi dei funzionari della Fed che hanno ribadito la visione secondo cui saranno necessari più dati che confermino la discesa dell’inflazione per convincere il Fomc a tagliare i tassi. Anche la crescita degli indici Pmi, che dipingono un’economia resiliente con persistenti pressioni al rialzo sui prezzi, rafforzano l’idea di tassi elevati ancora a lungo. Per continuare a leggere visita il link

  • Due nuove obbligazioni Societe Generale, in Euro e in Dollaro USA

    Societe Generale porta sul segmento Bond-X (EuroTLX) di Borsa Italiana due obbligazioni, una in EUR e una in USD, a tasso fisso decrescente con durata massima di 15 anni e possibilità di rimborso anticipato annuale a discrezione dell’Emittente.

    Per continuare a leggere visita questo LINK
ti auguro il meglio, comunque, tieni presente che uno split non è mai una buona cosa....a meno che non vogliano fare un uplisting al nasdaq

se hai dei dubbi, chiedi al gra$$one :D
 
ti auguro il meglio, comunque, tieni presente che uno split non è mai una buona cosa....a meno che non vogliano fare un uplisting al nasdaq

se hai dei dubbi, chiedi al gra$$one :D

Ciao Gabry, nei prossimi giorni, se puoi ci sentiamo su questo.

Hai ragione di solito RS non è buono soprattutto in OTC ma qui credo sia diverso. D'altra parte se avessero voluto fregare gli azionisti avrebbero fatto 1:100-500 e non 1:8, e lo hanno fatto per le ragioni spiegate dallo stesso CEO. E' chiaro tutto può succedere, ma credo che questi vogliono proprio l'Uplisting.
 
Ciao Gabry, nei prossimi giorni, se puoi ci sentiamo su questo.

Hai ragione di solito RS non è buono soprattutto in OTC ma qui credo sia diverso. D'altra parte se avessero voluto fregare gli azionisti avrebbero fatto 1:100-500 e non 1:8, e lo hanno fatto per le ragioni spiegate dallo stesso CEO. E' chiaro tutto può succedere, ma credo che questi vogliono proprio l'Uplisting.

guarda, ho mia madre in terapia intensiva, lascia perdere che ho la testa altrove..
 
NEWS -- Vivos Inc. Enhances its Intellectual Property Protection

Richland WA, July 02, 2019 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCPINK:RDGLD), Vivos today announced the filing of a patent application covering key aspects of its technology and propriety manufacturing process.

Vivos CEO, Dr. Mike Korenko stated “enhancing and extending our intellectual property protection is a core priority for Vivos. Over the past two years we have made significant improvements in our manufacturing processes and corresponding enhancements in our underlying technology. These advancements represent proprietary knowledge in key areas, and we believe this additional patent protection will strengthen our competitive position. It is our intention to further extend this patent protection to several key countries within one year, as permitted under international patent laws and treaties.”

Dr. Korenko continued, “this most recent patent filing is an important next step for Vivos that builds upon our existing license agreement with Battelle Pacific Northwest Laboratory, our current US and International trademark protection and other proprietary practices. In accordance with patent law, this patent filing addresses new aspects of Vivos’ technology that have not yet been reported publicly or offered for sale. The timing of this filing is important given our plans to make IsoPet® commercially available in the near future. We intend to incorporate this enhanced technology as soon as possible for commercial sales of IsoPet®.”

About Vivos Inc. (OTC:RDGLD)

Vivos Inc. is a pharmaceutical company researching and developing minimally invasive treatments to combat cancer in humans and animals. It has developed an Yttrium-90 based brachytherapy injectable device, for the treatment of tumors in animals (IsoPet®) and in humans (Radiogel™). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the company’s proprietary hydrogel formulation. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.

IsoPet® is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. This hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial space after injection to keep the radiation source safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

IsoPet® also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to the family.

The IsoPet® Solutions division is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. The testing on feline sarcoma at the Washington State University is completed and the testing on canine soft tissue sarcomas at the University of Missouri is currently underway.

The Company recently obtained confirmation from the FDA Center for Veterinary Medicine that IsoPet® is classified as a device according to its intended use and means by which it achieves its intended purpose. The FDA also reviewed the product labeling which included canine and feline sarcomas as the initial indications for use. FDA does not require pre-market approval for veterinary devices so no additional approval is required for treating skin cancer, which is the largest market sector. Following this demonstration phase, Vivos can begin to generate revenues through the sale of IsoPet® to University animal hospitals and private veterinary clinic consortiums.

IsoPet® for treating animals uses the same technology as RadioGel™ for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.

The Company is also engaging the FDA for premarket clearance to market RadioGel™ for the treatment of advanced basal and squamous cell skin cancers in humans.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.

CONTACT:

Vivos Inc.
Michael K. Korenko, President & CEO
mailto://MKorenko@RadioGel.com
 
hai sempre tutto il malloppone? (o hai incrementato ancora?:clap::censored:)
 
Vivos Inc. Pilot Clinic Completes Their Certification Training
BY GlobeNewswire
— 7:00 AM ET 07/09/2019

Richland WA, July 09, 2019 (GLOBE NEWSWIRE) -- Vivos Inc. (RDGL) Vivos, Inc. ( RDGLD ) is pleased to announce that Vista Veterinary Hospital has completed its first Isopet® certification training for two verterinary professionals, with more expected in the near future.

Employee certification is the last major step prior to offering public participation in our commercial IsoPet® therapy development program. We are currently finalizing the administrative details. Since Vista is the first clinic offering the Isopet® therapy, we will be screening applications using a disciplined process. We are near completion of our a web page portal for interested pet owners to submit their Expression of Interest Application. These will be reviewed by Vista. Any direct callers to Vista will be included in this same screening process. Our first patient has already been identified.

Dr. Mike Korenko stated “reaching this point is exciting. It is based on a disciplined approach, which is necessary when bringing a new cancer therapy product to market. We look forward to extending and improving the quality of life of many pets, while at the same time collecting data for our interactions with the FDA. We intend to gain experience and generate therapy data at Vista for several months before expanding to other regional clinics. All data will be shared with the veterinary oncology community.”

In addition, Dr. Charles Maitz will be formally presenting the results from the University of Missouri Isopet® developmental therapy study at the Veterinary Cancer Society Conference that is being held in October.”
 
Vivos Inc. Pilot Clinic Completes First IsoPet® Therapy

July 11, 2019 07:00 ET | Source: Vivos Inc.

Richland WA, July 11, 2019 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCPINK: RDGLD), Dr. Michelle Meyers, IsoPet® certified veterinarian practicing at Vista Veterinary Hospital, treated their first patient, a cat named Drake. The patient has already been released since this is same-day therapy.

Drake’s spindle cell sarcoma had been treated previously with external beam therapy but the tumor reoccurred. In this therapy Dr. Meyer focused on treating the margins around the tumor to reduce the chance of re-occurrence. The pet’s owner is a veterinarian from Sitka Alaska. He had researched the options and decided that IsoPet was his best choice to extend the life of his cat.

Dr. Mike Korenko stated “This therapy is the culmination of more than two years of dedicated work to bring Isopet® to market. We will be screening patients for future therapies. The current pricing for Isopet® is competitive with external beam therapy, with the advantage that Y-90 IsoPet® can deliver much higher doses in a single treatment and is precision targeted with insignificant collateral damage to healthy tissue. Over time and as patient volumes increases, we will continue to work to reduce production costs to significantly expand our customer base.” Isopet® provides certified veterinarians with an on-demand next generation cancer therapy alternative without the significant capital expenditure associated with traditional beam therapy. Pet owners who choose Isopet® will know that this important expenditure provides their pet with a powerful new treatment that can dramatically enhance quality of life without the need for the repeated treatment typically required by traditional beam therapy.”

We have created a portal on our web page for interested pet owners to submit their Expression of Interest Application. These will be reviewed by Vista Veterinary Hospital. Any direct callers to Vista will be sent this same application and they will be included in this same screening process.
 
Ed anche questa è partita per zona dollarland....multidollar:censored::censored:
 
;)
 

Allegati

  • sc.png
    sc.png
    18,5 KB · Visite: 114
Quanta bella gente che circola in OTC.....grandi manovre in esecuzione:cool::cool:
 
Indietro